ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

SAN FRANCISCO -- A company hoping to market an inhalable formulation of interferon beta for viral lung diseases isn't dissuaded by phase III trial results in 623 hospitalized COVID-19 patients, which ...

A new paper from the University of Kansas overturns the idea that a "risk gene" carried by millions of people worldwide ...

Data reviewed in this article demonstrate that both interferon-ß-1a (IFNß-1a) and interferon-ß-1b (IFNß-1b) show a dose-response relationship in multiple sclerosis at current clinical doses. Moreover, ...

A new paper from the University of Kansas overturns the idea that a "risk gene" carried by millions of people worldwide ...

September 25, 2012 (Vienna, Austria) — There is still no cure for the common cold, but interferon-β significantly decreases the frequency of cold-induced exacerbations in people with ...

This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major ...

DUBLIN--(BUSINESS WIRE)--The "Interferon - Biosimilar Insight, 2020" report has been added to ResearchAndMarkets.com's offering. This Interferon-Biosimilar Insight, 2020 report provides comprehensive ...

The Covid-19 pandemic is characterized by successive waves of infection driven by variants that have evolved to become more transmissible and immune evasive. Much of the attention has focused on ...